A brain slice culture model of viral encephalitis reveals an innate CNS cytokine response profile and the therapeutic potential of caspase inhibition.
Viral encephalitis is a significant cause of human morbidity and mortality in large part due to suboptimal diagnosis and treatment. Murine reovirus infection serves as a classic experimental model of viral encephalitis. Infection of neonatal mice with T3 reoviruses results in lethal encephalitis associated with neuronal infection, apoptosis, and CNS tissue injury. We have developed an ex vivo brain slice culture (BSC) system that recapitulates the basic pathological features and kinetics of viral replication seen in vivo. We utilize the BSC model to identify an innate, brain-tissue specific inflammatory cytokine response to reoviral infection, which is characterized by the release of IL6, CXCL10, RANTES, and murine IL8 analog (KC). Additionally, we demonstrate the potential utility of this system as a pharmaceutical screening platform by inhibiting reovirus-induced apoptosis and CNS tissue injury with the pan-caspase inhibitor, Q-VD-OPh. Cultured brain slices not only serve to model events occurring during viral encephalitis, but can also be utilized to investigate aspects of pathogenesis and therapy that are not experimentally accessible in vivo.
Medical Scientist Training Program, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO 80045, USA.
Kalen R
KR
Dionne
J Smith
JS
Leser
Kristi A
KA
Lorenzen
J David
JD
Beckham
Kenneth L
KL
Tyler
D000818:Animals; D000831:Animals, Newborn; D061945:Caspase Inhibitors; D020169:Caspases / Q000502:physiology; D016207:Cytokines / Q000096:biosynthesis* / Q000378:metabolism; D004195:Disease Models, Animal; D018792:Encephalitis, Viral / Q000188:drug therapy* / Q000201:enzymology / Q000276:immunology*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D007113:Immunity, Innate; D051379:Mice; D009410:Nerve Degeneration / Q000188:drug therapy / Q000201:enzymology / Q000276:immunology; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009924:Organ Culture Techniques; D012088:Reoviridae Infections / Q000188:drug therapy* / Q000201:enzymology / Q000276:immunology*
D061945:Caspase Inhibitors; D016207:Cytokines; D004791:Enzyme Inhibitors; D018696:Neuroprotective Agents; D020169:Caspases
Exp Neurol. 2003 Jan;179(1):47-59
12504867
Herpes. 2004 Jun;11 Suppl 2:57A-64A
15319091
Proc Natl Acad Sci U S A. 1998 May 26;95(11):6448-53
9600986
J Gen Virol. 2006 Oct;87(Pt 10):2827-2837
16963740
J Infect Dis. 2004 Nov 1;190(9):1618-26
15478067
Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):7041-6
10359835
Cytokine. 2009 May;46(2):187-93
19261488
J Virol. 2002 Jul;76(14):7247-54
12072524
J Virol. 2009 Jun;83(12):6161-70
19321603
Ann N Y Acad Sci. 2004 Jun;1018:533-40
15240412
J Virol. 2007 Mar;81(6):2614-23
17192305
J Neuroinflammation. 2005 Nov 15;2:25
16285888
J Virol. 2004 May;78(10):5466-75
15113925
BMC Microbiol. 2007 May 29;7:49
17535425
Brain Res. 2004 Jan 16;996(1):47-54
14670630
J Infect Dis. 2008 Oct 1;198(7):1002-6
18710325
J Antimicrob Chemother. 2007 Nov;60(5):981-6
17872917
Brain Res. 2004 Mar 19;1001(1-2):125-32
14972661
N Engl J Med. 2004 Jul 22;351(4):370-8
15269317
Neurology. 2001 Jul 24;57(2):295-9
11468315
Viral Immunol. 2005;18(1):89-115
15802955
J Neurovirol. 2002 Oct;8(5):365-80
12402163
J Neurovirol. 2010 Feb;16(1):56-71
20158406
J Neurosci Methods. 1991 Apr;37(2):173-82
1715499
Epilepsia. 2010 Aug;51(8):1493-502
20067512
Hepatology. 1998 Jun;27(6):1475-82
9620316
J Virol. 1997 Mar;71(3):2100-6
9032342
Emerg Infect Dis. 2010 Jan;16(1):139-42
20031062
J Neurosci. 2003 Nov 26;23(34):10756-64
14645467
Neurosci Res. 2003 Aug;46(4):523-32
12871774
J Virol. 1999 Jan;73(1):695-701
9847375
J Gen Virol. 2008 Aug;89(Pt 8):1930-1941
18632964
Biophys J. 2003 Jan;84(1):687-95
12524321
Curr Neuropharmacol. 2007 Mar;5(1):19-33
18615151
J Virol. 2007 Jul;81(13):6984-92
17475657
Brain Res Brain Res Protoc. 1999 Jan;3(3):278-90
9974143
Neurosci Lett. 2010 Mar 31;473(1):48-51
20153811
Brain Dev. 2009 Nov;31(10):731-8
19114298
Clin Infect Dis. 2002 Aug 1;35(3):254-60
12115090
J Neurovirol. 2003 Feb;9(1):101-11
12587073
Neurochem Int. 2004 Jul;45(1):117-27
15082229
J Infect Dis. 2002 Dec 1;186(11):1547-57
12447729
J Virol. 2004 Oct;78(20):11040-50
15452224
Curr Top Microbiol Immunol. 2005;289:57-77
15791951
Oncogene. 1999 Nov 11;18(47):6505-12
10597253
J Virol. 2004 Feb;78(3):1212-8
14722276
J Virol. 2005 Sep;79(18):11716-23
16140749
Epilepsia. 2004 Apr;45(4):322-32
15030494
J Neurosci. 2009 Nov 4;29(44):13761-9
19889988
J Neurovirol. 2010 Jul;16(4):306-17
20626234
J Med Microbiol. 2000 Jul;49(7):607-612
10882085
Exp Neurol. 2005 Apr;192(2):331-9
15755550
J Neurovirol. 2007 Aug;13(4):373-83
17849321
Exp Neurol. 1995 Apr;132(2):209-19
7540554
Epilepsia. 2010 Jan;51(1):127-35
19674053
Trends Neurosci. 1997 Oct;20(10):471-7
9347615
Brain Res. 2000 Apr 7;861(1):143-50
10751574
Neurology. 2008 Oct 7;71(15):1160-6
18838663
J Neurosci Res. 2004 Jul 15;77(2):217-28
15211588